11 Jul 2024 • The ADAPTABLE study found no significant sex-specific differences in the primary effectiveness and safety between the two aspirin doses evaluated (81 mg vs 325 mg) for the secondary prevention of atherosclerotic cardiovascular disease.

• The trial included 15,076 patients (68.7% male) aged 18 years and older with chronic atherosclerotic cardiovascular disease (ASCVD). Participants were randomized to receive either 81 mg or 325 mg of aspirin daily. The outcomes of all-cause death and hospitalization for myocardial infarction (MI) or stroke, showed no significant difference between the two aspirin doses in both female (adjusted hazard ratio [aHR] for 81 mg vs 325 mg: 1.01) and male participants (aHR: 1.06). There was no significant interaction by sex for this primary endpoint (P interaction = 0.74).

• Female participants had fewer revascularization procedures (5.0% vs 6.6%, aHR 0.79) but a higher risk of hospitalization for stroke (aHR 1.72) compared to male participants. Additionally, among female participants, there was a trend towards higher bleeding risk with the 81 mg aspirin dose compared to the 325 mg dose (aHR 2.21).

Source:JAMA| Read full story